{"created":"2021-09-28T01:10:04.059171+00:00","id":2001441,"links":{},"metadata":{"_buckets":{"deposit":"8477da64-7d72-4237-974e-fc1d6739be56"},"_deposit":{"created_by":25,"id":"2001441","owner":"25","owners":[25],"owners_ext":{"displayname":"wataka","username":"kuma1008"},"pid":{"revision_id":0,"type":"depid","value":"2001441"},"status":"published"},"_oai":{"id":"oai:tsukuba.repo.nii.ac.jp:02001441","sets":["2780:1781","3:62:5298:7829"]},"author_link":["204282","636"],"item_5_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2020-06","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"6","bibliographicPageStart":"1690","bibliographicVolumeNumber":"12","bibliographic_titles":[{"bibliographic_title":"Cancers","bibliographic_titleLang":"en"}]}]},"item_5_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Background: Androgen deprivation therapy (ADT) combined with radiation therapy benefits intermediate- and high-risk prostate cancer (PC) patients. The optimal ADT duration in combination with high-dose proton beam therapy (PBT) remains unknown. Methods: Intermediate- and high-risk PC patients treated with PBT combined with ADT for various durations were analyzed retrospectively. To assess the relationship between ADT and biochemical relapse-free (bRF) rate, Cox proportional hazards models including T stage, prostate specific antigen (PSA) level, Gleason score (GS), and total radiation dose were used. Results: In the intermediate-risk PC patients (n = 520), ADT use improved bRF (HR 0.49, 95% CI 0.26–0.93; p = 0.029), especially in those with multiple intermediate-risk factors (T2b–2c, PSA 10–20 ng/mL, and GS 7). In the high-risk PC patients (n = 555), a longer ADT duration (>6 months) conferred a benefit for bRF (HR 0.54, 95% CI 0.32–0.90; p = 0.018), which was most apparent in patients with multiple high-risk factors (T3a–4, PSA > 20 ng/mL, and GS ≥ 8) treated with ADT for ≥21 months. Conclusions: Short-term (≤6 months) ADT is beneficial for intermediate-risk PC patients, but likely unnecessary for those with a single risk factor, whereas ADT for >6 months is necessary for high-risk PC patients and ADT for ≥21 months might be optimal for those with multiple risk factors in combination of high-dose PBT.","subitem_description_language":"en","subitem_description_type":"Abstract"}]},"item_5_publisher_27":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"MDPI","subitem_publisher_language":"en"}]},"item_5_relation_10":{"attribute_name":"PubMed番号","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"32630494","subitem_relation_type_select":"PMID"}}]},"item_5_relation_11":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"https://doi.org/10.3390/cancers12061690","subitem_relation_type_select":"DOI"}}]},"item_5_rights_12":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).","subitem_rights_language":"en"}]},"item_5_select_15":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_select_item":"publisher"}]},"item_5_source_id_7":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"2072-6694","subitem_source_identifier_type":"EISSN"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"open access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_abf2"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Murakami, Motohiro","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Ishikawa, Hitoshi","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Shimizu, Shosei","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Iwata, Hiromitsu","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Okimoto, Tomoaki","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Takagi, Masaru","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Murayama, Shigeyuki","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Akimoto, Tetsuo","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Wada, Hitoshi","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Arimura, Takeshi","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Sato, Yoshitaka","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"五所, 正彦","creatorNameLang":"ja"},{"creatorName":"ゴショ, マサヒコ","creatorNameLang":"ja-Kana"},{"creatorName":"GOSHO, Masahiko","creatorNameLang":"en"}],"familyNames":[{},{},{}],"givenNames":[{},{},{}],"nameIdentifiers":[{},{},{}]},{"creatorNames":[{"creatorName":"Nakamura, Katsumasa","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"櫻井, 英幸","creatorNameLang":"ja"},{"creatorName":"サクライ, ヒデユキ","creatorNameLang":"ja-Kana"},{"creatorName":"SAKURAI, Hideyuki","creatorNameLang":"en"}],"familyNames":[{},{},{}],"givenNames":[{},{},{}],"nameIdentifiers":[{},{},{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_access","date":[{"dateType":"Available","dateValue":"2021-09-28"}],"displaytype":"detail","filename":"Cancers_12-6.pdf","filesize":[{"value":"1.1 MB"}],"format":"application/pdf","licensetype":"license_0","url":{"objectType":"fulltext","url":"https://tsukuba.repo.nii.ac.jp/record/2001441/files/Cancers_12-6.pdf"},"version_id":"f1e5b160-c4cc-4532-8082-5fc51f5804be"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Optimal Androgen Deprivation Therapy Combined with Proton Beam Therapy for Prostate Cancer: Results from a Multi-Institutional Study of the Japanese Radiation Oncology Study Group","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Optimal Androgen Deprivation Therapy Combined with Proton Beam Therapy for Prostate Cancer: Results from a Multi-Institutional Study of the Japanese Radiation Oncology Study Group","subitem_title_language":"en"}]},"item_type_id":"5","owner":"25","path":["3074","1781","7829"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2021-09-28"},"publish_date":"2021-09-28","publish_status":"0","recid":"2001441","relation_version_is_last":true,"title":["Optimal Androgen Deprivation Therapy Combined with Proton Beam Therapy for Prostate Cancer: Results from a Multi-Institutional Study of the Japanese Radiation Oncology Study Group"],"weko_creator_id":"25","weko_shared_id":-1},"updated":"2022-04-27T10:53:38.854476+00:00"}